Redesigning t-PA for improved thrombolytic therapy.

Abstract excerpt

Attempts are being made to redesign the structure of tissue-type plasminogen activator (t-PA) in order to increase its plasma half-life, increase its fibrin affinity or decrease its rate of interaction with plasma inhibitors. The principal strategies employed so far have been to construct hybrid enzymes, to mutate the polypeptide sequence of t-PA or to add extra fibrin-binding elements. It has been relatively...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Design
• Share to Amino Acids
• Share to Fibrin